Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ascendis Pharma logo — Committed to making a meaningful difference for patients

Ascendis Pharma

Committed to making a meaningful difference for patients

Founded 2007 Denmark Denmark 1046 employees Post-IPO Debt Total: $1.42B Biotechnology, Health Care

General Information

Company Name Ascendis Pharma
Founded Year 2007
Location Denmark Denmark
Employees 1046
Industries Biotechnology, Health Care
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Ascendis Pharma. To contact Ascendis Pharma, visit ascendispharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ascendis Pharma compare?

A PDF of Ascendis Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ascendis Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ascendis Pharma

Ascendis Pharma is a biopharmaceutical company committed to making a meaningful difference for patients. The company is guided by its core values of patients, science, and passion and is applying innovative TransCon technology to create new and potentially best-in-class therapies. Currently, Ascendis Pharma has three independent endocrinology rare disease product candidates in clinical development and is also advancing programs in Oncology and Ophthalmology. The company is headquartered in Copenhagen, Denmark with additional offices in Heidelberg, Munich, and Berlin, Germany, Palo Alto and Redwood City, California, and Princeton, New Jersey. Having been founded in 2006, Ascendis Pharma has seen significant investment, with the last investment of $150.00M Post-IPO Debt being made on 05 September 2023, with Royalty Pharma as the investors. The company operates within the Biotechnology and Health Care industries, positioning itself as an innovative leader in the field of biopharmaceuticals.

Business keywords: Biopharmaceutical, Rare Diseases, Clinical Development, Oncology, Ophthalmology, TransCon Technology, Drug Development, Innovation, Endocrinology, Prodrug Technology, Globalization, New Chemical Entities, Patient-Centric, High-Value Pipeline, Unmet Medical Need

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Debt $150.00M 1
Royalty Pharma
05 Sep 2023
Post IPO Debt $500.00M -
24 Mar 2022
Post IPO Equity $690.00M -
07 Jul 2020
Post IPO Equity Undisclosed 1
Sofinnova Investments
Sofinnova Investments
01 Jan 2017
Series D $60.00M 6
RA Capital Management Venrock OrbiMed
RA Capital Management, Venrock +4
01 Dec 2014
Series A €17.60M 2
Gilde Healthcare TechnoStart
Gilde Healthcare, TechnoStart
13 Dec 2007

Ascendis Pharma Alternatives & Competitors

View All Alternatives
Ascendis Pharma vs
Apollo Therapeutics
Apollo Therapeutics

A transformative idea for transformative medicines

Series C
59 employees
Biopharma, Biotechnology
Ascendis Pharma vs
CORXEL Pharmaceuticals
CORXEL Pharmaceuticals China

Our mission is to develop innovative cardiometabolic therapies globally.

Series D
40 employees
Biotechnology, Health Care
Compare Ascendis Pharma vs CORXEL Pharmaceuticals
Ascendis Pharma vs
AMO Pharma LTD
AMO Pharma LTD United States

AMO Pharma is working to develop novel therapeutics for rare genetic neurodevelopmental disorders

Series A
12 employees
Biotechnology, Health Care
View all alternatives

FAQ About Ascendis Pharma

Committed to making a meaningful difference for patients
Ascendis Pharma was founded in 2007.
Ascendis Pharma is headquartered in Denmark.
Ascendis Pharma operates in Biotechnology and Health Care. Its work centres on Biopharmaceutical, Rare Diseases, Clinical Development and Oncology.
Ascendis Pharma has approximately 1046 employees.
Ascendis Pharma has completed 6 funding rounds, raising a total of $1.42B. The latest funding stage is Post-IPO Debt.
Top alternatives and competitors to Ascendis Pharma include Apollo Therapeutics, CORXEL Pharmaceuticals, AMO Pharma LTD, Dualyx, Ultragenyx. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ascendis Pharma and Apollo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ascendis Pharma, https://bouncewatch.com/company/ascendis-pharma, updated 31 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout